Loading...

You're on the old version of Simply Wall St. We will no longer be supporting this site, so we recommend you switch to our brand new platform.

DocCheck

DB:AJ91
Snowflake Description

Flawless balance sheet average dividend payer.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
AJ91
DB
€49M
Market Cap
  1. Home
  2. DE
  3. Healthcare
Company description

DocCheck AG provides marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe. The last earnings update was 253 days ago. More info.


Add to Portfolio Compare Print
AJ91 Share Price and Events
7 Day Returns
0%
DB:AJ91
16.8%
DE Healthcare Services
2.1%
DE Market
1 Year Returns
13.1%
DB:AJ91
15.8%
DE Healthcare Services
-16.6%
DE Market
AJ91 Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
DocCheck (AJ91) 0% -7.8% -6.9% 13.1% 5.6% 58.7%
DE Healthcare Services 16.8% 4.4% -1.9% 15.8% 50.3% 117%
DE Market 2.1% -12.6% -22.9% -16.6% -21.9% -27.8%
1 Year Return vs Industry and Market
  • AJ91 underperformed the Healthcare Services industry which returned 15.8% over the past year.
  • AJ91 outperformed the Market in Germany which returned -16.6% over the past year.
Price Volatility
AJ91
Industry
5yr Volatility vs Market

Value

 Is DocCheck undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of DocCheck to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for DocCheck.

DB:AJ91 Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model Dividend Discount Model
Dividend Per Share Company Filings (2019-06-30) in EUR € .400000
Payout Ratio Company Filings (2019-06-30) 7755.4%
Discount Rate (Cost of Equity) See below 4.3%
Perpetual Growth Rate 10-Year DE Government Bond Rate -0.4%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:AJ91
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate -0.4%
Equity Risk Premium S&P Global 5.4%
Healthcare Services Unlevered Beta Simply Wall St/ S&P Global 0.79
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 0.794 (1 + (1- 30%) (0.05%))
0.862
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
0.86
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= -0.39% + (0.862 * 5.44%)
4.3%

Discounted Cash Flow Calculation for DB:AJ91 using Dividend Discount Model Model

The calculations below outline how an intrinsic value for DocCheck is arrived at by discounting future dividends to their present value. This approach is used for finance firms where free cash flow is difficult to estimate (e.g. Banks/ Insurance firms).

If the firm does not pay the majority of its earnings out as a dividend this method will often arrive at a value significantly lower than the share price.

See our documentation to learn about this calculation.

DB:AJ91 Gordon Growth Model
Calculation Result
Value per share = Expected dividends per share / (Discount Rate - Perpetual growth rate)
= €0.4 / (4.3% - -0.39%)
€8.02
DB:AJ91 Discount to Share Price
Calculation Result
Non-primary Listing Adjustment Factor 1 share in DB:AJ91 represents 0.96939x of XTRA:AJ91
(This could be a different class, a depositary receipt, a different currency, or all of these things.)
0.96939x
Value per Share
(Listing Adjusted, EUR)
= Value per Share (EUR) x Listing Adjustment Factor
= € 8.53 x 0.96939
€8.27
Value per share (EUR) From above. €8.27
Current discount Discount to share price of €9.50
= -1 x (€9.50 - €8.27) / €8.27
-14.9%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of DocCheck is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for DocCheck's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are DocCheck's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:AJ91 PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2019-06-30) in EUR €0.58
XTRA:AJ91 Share Price ** XTRA (2020-04-07) in EUR €9.8
Germany Healthcare Services Industry PE Ratio Median Figure of 6 Publicly-Listed Healthcare Services Companies 11.51x
Germany Market PE Ratio Median Figure of 402 Publicly-Listed Companies 16.83x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of DocCheck.

DB:AJ91 PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= XTRA:AJ91 Share Price ÷ EPS (both in EUR)

= 9.8 ÷ 0.58

16.79x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DocCheck is overvalued based on earnings compared to the DE Healthcare Services industry average.
  • DocCheck is good value based on earnings compared to the Germany market.
Price based on expected Growth
Does DocCheck's expected growth come at a high price?
Raw Data
DB:AJ91 PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section 16.79x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 0 Analysts
Not available
Europe Healthcare Services Industry PEG Ratio Median Figure of 14 Publicly-Listed Healthcare Services Companies 2.68x
Germany Market PEG Ratio Median Figure of 256 Publicly-Listed Companies 1.22x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for DocCheck, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on DocCheck's assets?
Raw Data
DB:AJ91 PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2019-06-30) in EUR €4.07
XTRA:AJ91 Share Price * XTRA (2020-04-07) in EUR €9.8
Germany Healthcare Services Industry PB Ratio Median Figure of 7 Publicly-Listed Healthcare Services Companies 2.82x
Germany Market PB Ratio Median Figure of 573 Publicly-Listed Companies 1.45x
DB:AJ91 PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= XTRA:AJ91 Share Price ÷ Book Value per Share (both in EUR)

= 9.8 ÷ 4.07

2.41x

* Primary Listing of DocCheck.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • DocCheck is good value based on assets compared to the DE Healthcare Services industry average.
X
Value checks
We assess DocCheck's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Healthcare Services industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Healthcare Services industry average (and greater than 0)? (1 check)
  5. DocCheck has a total score of 2/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is DocCheck expected to perform in the next 1 to 3 years based on estimates from 0 analysts?

In this section we usually present revenue and earnings growth projections based on the consensus estimates of professional analysts to help investors understand the company’s ability to generate profit. But as DocCheck has not provided enough past data and has no analyst forecast, its future earnings cannot be reliably calculated by extrapolating past data or using analyst predictions.

This is quite a rare situation as 97% of companies covered by Simply Wall St do have past financial data. You can see them here.

Show me the analysis anyway

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
26.9%
Expected Healthcare Services industry annual growth in earnings.
Earnings growth vs Low Risk Savings
Is DocCheck expected to grow at an attractive rate?
  • Unable to compare DocCheck's earnings growth to the low risk savings rate as no estimate data is available.
Growth vs Market Checks
  • Unable to compare DocCheck's earnings growth to the Germany market average as no estimate data is available.
  • Unable to compare DocCheck's revenue growth to the Germany market average as no estimate data is available.
Annual Growth Rates Comparison
Raw Data
DB:AJ91 Future Growth Rates Data Sources
Data Point Source Value (per year)
Europe Healthcare Services Industry Earnings Growth Rate Market Cap Weighted Average 26.9%
Europe Healthcare Services Industry Revenue Growth Rate Market Cap Weighted Average 8.1%
Germany Market Earnings Growth Rate Market Cap Weighted Average 14%
Germany Market Revenue Growth Rate Market Cap Weighted Average 3.9%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:AJ91 Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:AJ91 Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2019-06-30 30 3 3
2019-03-31 29 4 3
2018-12-31 28 4 2
2018-09-30 29 3 2
2018-06-30 29 3 2
2018-03-31 28 3 2
2017-12-31 28 3 2
2017-09-30 28 3 3
2017-06-30 27 3 3
2017-03-31 26 3 3
2016-12-31 26 3 3
2016-09-30 26 3

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • Unable to determine if DocCheck is high growth as no earnings estimate data is available.
  • Unable to determine if DocCheck is high growth as no revenue estimate data is available.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:AJ91 Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below

All data from DocCheck Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AJ91 Past Financials Data
Date (Data in EUR Millions) EPS *
2019-06-30 0.58
2019-03-31 0.52
2018-12-31 0.46
2018-09-30 0.44
2018-06-30 0.42
2018-03-31 0.45
2017-12-31 0.48
2017-09-30 0.51
2017-06-30 0.54
2017-03-31 0.54
2016-12-31 0.53
2016-09-30 0.54

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if DocCheck will efficiently use shareholders’ funds in the future without estimates of Return on Equity.

Next steps:

  1. Examine DocCheck's financial health to determine how well-positioned it is against times of financial stress by looking at its level of debt over time and how much cash it has left.
  2. DocCheck's future outlook can be gauged by looking at industry trends and market size, and determining how well-positioned the company is compared to its competitors. Take a look at other high-growth Healthcare companies here
  3. DocCheck's competitive advantages and company strategy can generally be found in its financial reports archived here.
  4. Use fundamentals to screen for another stock to analyse from our database of over 75,000 companies worldwide
X
Future performance checks
We assess DocCheck's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
DocCheck has a total score of 0/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has DocCheck performed over the past 5 years?

  • DocCheck's last earnings update was 253 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare DocCheck's growth in the last year to its industry (Healthcare Services).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • DocCheck's year on year earnings growth rate has been positive over the past 5 years.
  • DocCheck's 1-year earnings growth exceeds its 5-year average (37.6% vs 5.7%)
  • DocCheck's earnings growth has exceeded the DE Healthcare Services industry average in the past year (37.6% vs 5.9%).
Earnings and Revenue History
DocCheck's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from DocCheck Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:AJ91 Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2019-06-30 29.97 2.91 1.17
2019-03-31 29.16 2.59 1.17
2018-12-31 28.34 2.27 1.17
2018-09-30 28.62 2.20 1.05
2018-06-30 28.91 2.12 0.93
2018-03-31 28.50 2.26 0.93
2017-12-31 28.08 2.41 0.93
2017-09-30 27.52 2.55 0.87
2017-06-30 26.95 2.70 0.81
2017-03-31 26.44 2.68 0.81
2016-12-31 25.94 2.66 0.81
2016-09-30 26.37 2.72 0.82
2016-06-30 26.81 2.77 0.82
2016-03-31 26.81 2.83 0.82
2015-12-31 26.82 2.88 0.82
2015-09-30 24.70 2.45 0.81
2015-06-30 22.58 2.02 0.81
2015-03-31 21.24 1.86 0.81
2014-12-31 19.91 1.69 0.81
2014-09-30 19.19 1.63 0.75
2014-06-30 18.48 1.57 0.69
2014-03-31 18.14 1.33 0.69
2013-12-31 17.80 1.09 0.69
2013-09-30 17.80 0.95 0.68
2013-06-30 17.79 0.81 0.67

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • DocCheck has not efficiently used shareholders’ funds last year (Return on Equity less than 20%).
  • DocCheck used its assets less efficiently than the DE Healthcare Services industry average last year based on Return on Assets.
  • DocCheck's use of capital deteriorated last year versus 3 years ago (Return on Capital Employed).
X
Past performance checks
We assess DocCheck's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Healthcare Services industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
DocCheck has a total score of 3/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is DocCheck's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up DocCheck's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • DocCheck is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • DocCheck's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of DocCheck's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • Debt is covered by short term assets, assets are 616.6x debt.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from DocCheck Company Filings, last reported 9 months ago.

DB:AJ91 Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2019-06-30 20.35 0.02 8.69
2019-03-31 20.35 0.02 8.69
2018-12-31 20.90 0.03 10.42
2018-09-30 20.90 0.03 10.42
2018-06-30 19.28 0.03 7.39
2018-03-31 19.28 0.03 7.39
2017-12-31 20.63 0.03 9.13
2017-09-30 20.63 0.03 9.13
2017-06-30 19.16 0.03 8.35
2017-03-31 19.16 0.03 8.35
2016-12-31 20.17 0.04 9.43
2016-09-30 20.17 0.04 9.43
2016-06-30 18.36 0.04 7.85
2016-03-31 18.36 0.04 7.85
2015-12-31 19.66 0.04 9.54
2015-09-30 19.66 0.04 9.54
2015-06-30 17.69 0.02 8.88
2015-03-31 17.69 0.02 8.88
2014-12-31 18.59 0.03 9.45
2014-09-30 18.59 0.03 9.45
2014-06-30 17.63 0.03 8.50
2014-03-31 17.63 0.03 8.50
2013-12-31 17.93 0.03 7.12
2013-09-30 17.93 0.03 7.12
2013-06-30 17.03 0.03 6.27
  • DocCheck's level of debt (0.1%) compared to net worth is satisfactory (less than 40%).
  • The level of debt compared to net worth has been reduced over the past 5 years (0.2% vs 0.1% today).
  • Debt is well covered by operating cash flow (12907.9%, greater than 20% of total debt).
  • Interest payments on debt are well covered by earnings (EBIT is 13.1x coverage).
X
Financial health checks
We assess DocCheck's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. DocCheck has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is DocCheck's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
4.08%
Current annual income from DocCheck dividends.
If you bought €2,000 of DocCheck shares you are expected to receive €82 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • DocCheck's pays a higher dividend yield than the bottom 25% of dividend payers in Germany (1.67%).
  • DocCheck's dividend is below the markets top 25% of dividend payers in Germany (4.71%).
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:AJ91 Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 0 Analyst Estimates (S&P Global) See Below
Europe Healthcare Services Industry Average Dividend Yield Market Cap Weighted Average of 10 Stocks 1.4%
Germany Market Average Dividend Yield Market Cap Weighted Average of 314 Stocks 3.7%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.7%
Germany Top 25% Dividend Yield 75th Percentile 4.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:AJ91 Past Annualized Dividends Data
Date (Data in €) Dividend per share (annual) Avg. Yield (%)
2019-04-09 0.400 4.340
2018-04-19 0.400 4.721
2017-04-11 0.400 4.115
2016-03-31 0.400 5.136
2015-05-04 0.350 5.114
2012-03-14 0.250 5.940
2011-04-26 0.200 4.816
2010-04-07 0.050 1.413

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Dividends per share have been stable in the past 10 years.
  • Dividends per share have increased over the past 10 years.
Current Payout to shareholders
What portion of DocCheck's earnings are paid to the shareholders as a dividend.
  • Dividends paid are covered by earnings (1.5x coverage).
Future Payout to shareholders
  • Insufficient estimate data to determine if a dividend will be paid in 3 years and that it will be sustainable.
X
Income/ dividend checks
We assess DocCheck's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can DocCheck afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. DocCheck has a total score of 4/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of DocCheck's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
CEO
Frank Antwerpes
COMPENSATION €244,037
CEO Bio

Dr. Frank Nicolas Antwerpes serves as a Chief Executive Officer at DocCheck Guano AG. He served as the Chief Executive Officer of DocCheck Medizinbedarf und Logistik GmbH. Dr. Antwerpes serves as President of The Management Board and Chief Executive Officer of DocCheck AG. He serves as President of The Management Board and Chief Executive Officer of DocCheck AG (formerly Antwerpes AG). Dr. Antwerpes served as Chief Executive Officer of DocCheck Medical Services GmbH, a subsidiary of DocCheck AG. Dr. Antwerpes served as Chief Executive Officer of Antwerpes & Partner AG, a subsidiary of Antwerpes AG. Dr. Antwerpes serves as Chairman of the Supervisory Board of Antwerpes & Partner AG, a subsidiary of Antwerpes AG. He serves as Executive Director of DocCheck AG. He served as Dr. Antwerpes served as Chairman of the Board of DocCheck Medizinbedarf und Logistik GmbH. Executive Director of DocCheck Medical Services GmbH. He secured Med Exec program from Singularity University (2012), went to Heinrich-Heine-Universität Düsseldorf (1986-1991) and University of Cologne (1979-1985).

CEO Compensation
  • Frank's compensation has been consistent with company performance over the past year, both up more than 20%.
  • Frank's remuneration is lower than average for companies of similar size in Germany.
Management Team Tenure

Average tenure of the DocCheck management team in years:

0.7
Average Tenure
  • The average tenure for the DocCheck management team is less than 2 years, this suggests a new team.
Management Team

Frank Antwerpes

TITLE
President of the Management Board & CEO
COMPENSATION
€244K

Philip Stadtmann

TITLE
CFO & Member of Management Board
TENURE
0.7 yrs

Thilo Kölzer

TITLE
COO & Member of Management Board
TENURE
0.7 yrs

Jens Knoop

TITLE
CTO & Member of Management Board
TENURE
0.7 yrs

Roland Ortloff

TITLE
Chief Executive of Albert Geisselmann Medizinbedarf Gmbh

Stefan Kellner

TITLE
Unit Manager of Digital Communication and Member of the Management Board of Antwerpes & Partner Ag

Tanja Antwerpes

TITLE
Unit Manager of Classic Communication and Member of the Management Board of Antwerpes & Partner Ag
Board of Directors Tenure

Average tenure of the DocCheck board of directors in years:

6.9
Average Tenure
  • The tenure for the DocCheck board of directors is about average.
Board of Directors

Joachim Pietzko

TITLE
Chairman of the Supervisory Board
COMPENSATION
€29K
TENURE
6.9 yrs

Britta Böckmann

TITLE
Vice-President of the Supervisory Board
COMPENSATION
€14K
TENURE
6.9 yrs

Winfried Leimeister

TITLE
Member of Supervisory Board
COMPENSATION
€14K
TENURE
21.3 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month open market individual insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess DocCheck's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. DocCheck has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

Here's What DocCheck AG's (FRA:AJ91) P/E Ratio Is Telling Us

The formula for price to earnings is: Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS) Or for DocCheck: P/E of 18.64 = €8.5 ÷ €0.46 (Based on the trailing twelve months to December 2018.) Is A High Price-to-Earnings Ratio Good? … The higher the P/E ratio, the higher the price tag of a business, relative to its trailing earnings. … Although the recent drop in earnings per share would keep the market cautious, the healthy balance sheet means the company retains potential for future growth.

Simply Wall St -

DocCheck AG (FRA:AJ91): Commentary On Fundamentals

AJ91 is a dependable dividend payer that has been able to sustain great financial health over the past. … DB:AJ91 Historical Debt, July 18th 2019 For those seeking income streams from their portfolio, AJ91 is a robust dividend payer as well. … DB:AJ91 Historical Dividend Yield, July 18th 2019 Next Steps: For DocCheck, there are three essential aspects you should look at: Future Outlook: What are well-informed industry analysts predicting for AJ91’s future growth?

Simply Wall St -

What Kind Of Shareholders Own DocCheck AG (FRA:AJ91)?

Our analysis of the ownership of the company, below, shows that institutional investors have not yet purchased much of the company. … Check out our latest analysis for DocCheck DB:AJ91 Ownership Summary, June 26th 2019 What Does The Institutional Ownership Tell Us About DocCheck? … Insider Ownership Of DocCheck While the precise definition of an insider can be subjective, almost everyone considers board members to be insiders.

Simply Wall St -

Did DocCheck's (FRA:AJ91) Share Price Deserve to Gain 100%?

For example, the DocCheck AG (FRA:AJ91) share price is up 100% in the last 5 years, clearly besting than the market return of around 5.3% (ignoring dividends). … As well as measuring the share price return, investors should also consider the total shareholder return (TSR). … A Different Perspective It's nice to see that DocCheck shareholders have received a total shareholder return of 0.9% over the last year.

Simply Wall St -

Is DocCheck AG's (FRA:AJ91) 11% ROE Better Than Average?

With that in mind, this article will work through how we can use Return On Equity (ROE) to better understand a business. … The formula for return on equity is: … Return on Equity = Net Profit ÷ Shareholders' Equity

Simply Wall St -

Is DocCheck AG (FRA:AJ91) An Attractive Dividend Stock?

Today we'll take a closer look at DocCheck AG (FRA:AJ91) from a dividend investor's perspective. Owning a strong dividend company and reinvesting the dividends is widely seen as an attractive way of growing your wealth.. … Yet sometimes, investors buy a stock for its dividend and lose money because the share price falls by more than they earned in dividend payments.. … Before you buy any stock for its dividend however, you should always remember Warren Buffett's two rules: 1) Don't lose money, and 2) Remember rule #1

Simply Wall St -

Is DocCheck AG's (FRA:AJ91) CEO Pay Justified?

This analysis aims first to contrast CEO compensation with other companies that have similar market capitalization. … How Does Frank Antwerpes's Compensation Compare With Similar Sized Companies. … According to our data, DocCheck AG has a market capitalization of €42m, and pays its CEO total annual compensation worth €237k.

Simply Wall St -

Is DocCheck AG’s (FRA:AJ91) Return On Capital Employed Any Good?

Specifically, we're going to calculate its Return On Capital Employed (ROCE), in the hopes of getting some insight into the business. … Return On Capital Employed (ROCE): What is it? … ROCE is a measure of a company's yearly pre-tax profit (its return), relative to the capital employed in the business.

Simply Wall St -

Investors Who Bought DocCheck Shares Five Years Ago Are Now Up 84%

For example, long term DocCheck AG (FRA:AJ91) shareholders have enjoyed a 84% share price rise over the last half decade, well in excess of the market return of around 12% (not including dividends). … One flawed but reasonable way to assess how sentiment around a company has changed is to compare the earnings per share (EPS) with the share price. … Over half a decade, DocCheck managed to grow its earnings per share at 21% a year.

Simply Wall St -

Here's What DocCheck AG's (FRA:AJ91) P/E Ratio Is Telling Us

This article is written for those who want to get better at using price to earnings ratios (P/E ratios). … We'll show how you can use DocCheck AG's (FRA:AJ91) P/E ratio to inform your assessment of the investment opportunity. … Price to Earnings Ratio = Share Price ÷ Earnings per Share (EPS)

Simply Wall St -

Company Info

Description

DocCheck AG provides marketing, customer relationship management, and e-commerce services for the healthcare sector in Europe. The company operates DocCheck portal for exchanging information on the Internet, and online and e-commerce services for healthcare market players. It also develops and implements communication strategies for new and traditional media on healthcare and business-to-business sectors; and promotes healthcare startups through seed funding. DocCheck AG is based in Cologne, Germany.

Details
Name: DocCheck AG
AJ91
Exchange: DB
Founded:
€48,900,196
4,989,816
Website: http://www.doccheck.ag
Address: DocCheck AG
Vogelsanger Str. 66,
Cologne,
50823,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
XTRA AJ91 Bearer Shares XETRA Trading Platform DE EUR 17. Apr 2000
DB AJ91 Bearer Shares Deutsche Boerse AG DE EUR 17. Apr 2000
Number of employees
Current staff
Staff numbers
262
DocCheck employees.
Industry
Health Care Technology
Healthcare
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2020/04/08 02:30
End of day share price update: 2020/04/07 00:00
Last earnings filing: 2019/07/30
Last earnings reported: 2019/06/30
Last annual earnings reported: 2018/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.